In in vivo experiments, silencing SRSF3 significantly decreased tumor development and progression, likely by affecting the platelet-derived growth factor receptor beta (PDGFRB) pathway, which plays a critical role in tumor growth and angiogenesis [37]. This evidence concerns the gene PDGFRB and neoplasm.